A 31-residue acylated glucagon-like-peptide-1 analogue supplied as a lyophilised research material. It is studied in controlled laboratory models involving GLP-1-receptor activation, incretin signalling, glucose-responsive cellular pathways and modified-peptide stability.
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
Research context
It is structurally related to human GLP-1 and contains sequence substitutions together with a spacer-linked C18 fatty di-acid modification. Published pharmacology describes selective activation of the GLP-1 receptor and prolonged exposure associated with albumin binding and resistance to DPP-4 degradation.
A substantial clinical literature exists for this regulated medicine in defined patient populations, examining metabolic, glycaemic, appetite and cardiovascular endpoints. Those findings concern authorised or investigational pharmaceutical preparations used under controlled protocols; they do not establish the identity, purity, performance or suitability of the research material supplied on this page.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the compound, vial size and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied in the vial size selected above.
- Provided as a lyophilised research material.
- Keep the vial sealed and protected from moisture, heat and direct light.
- Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.
Frequently asked questions
What is S-Series?
It is a modified, acylated GLP-1 analogue studied as an agonist of the glucagon-like-peptide-1 receptor.
Which receptor is associated with S-Series research?
Published pharmacology primarily associates it with the GLP-1 receptor, a class-B G-protein-coupled receptor involved in incretin signalling.
How does S-Series differ from native GLP-1?
It contains amino-acid substitutions and a spacer-linked fatty di-acid side chain. These structural changes affect enzymatic stability and albumin association, so it should not be treated as identical to native GLP-1.
Which vial sizes are available?
Current selectable vial sizes and availability are shown above. These controls update automatically as variations change.
Are laboratory results available?
A shield appears beside a variation only when a published result is available. No indicator means that no product-specific result is currently displayed for that variation.
How should the material be stored?
See the Storage Guidelines tab for the current handling guidance for sealed lyophilised material and reconstituted solution.
Information reviewed 29 August 2026.
